IR Thematic Call on Multiple Sclerosis
|
|
- Bathsheba Cain
- 5 years ago
- Views:
Transcription
1 Teresa, Multiple Sclerosis, United States IR Thematic Call on Multiple Sclerosis October 3 rd, 2013
2 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding, as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. 2
3 Agenda Key Highlights on Multiple Sclerosis Market Bill Sibold - Senior Vice President, Head of Multiple Sclerosis - Genzyme Clinical Data Highlights Michael Panzara, MD, MPH - Therapeutic Area Head of MS & Neurology - Genzyme Genzyme MS Global Launch Update Bill Sibold - Senior Vice President, Head of Multiple Sclerosis - Genzyme Q&A Session 3
4 Multiple Sclerosis Market: Key Highlights Bill Sibold SVP, Head of Multiple Sclerosis - Genzyme 4
5 Global MS Market - Significant and Growing Market Key Multiple Facts Sclerosis about MS Serious disease with significant unmet medical needs Multiple Sclerosis Market Global Sales (3) > 14bn Symptoms include fatigue, weakness, walking and balance difficulties, vision problems ~ 11bn ~40% ~60% A major impact on family, social and professional life ~ 5bn ~2.1m patients worldwide (1) 2017e ~410,000 patients in the U.S. (1) ~630,000 patients in EU (2) ~50% ~50% U.S. ROW growth driven by new therapies, satisfying the unmet needs of convenient administration and more efficacious therapy (1) National Multiple Sclerosis Society (2) (3) Adapted from Evaluate Pharma July 2013; Reported sales of Copaxone, Avonex, Rebif, Betaseron/Betaferon, Extavia, Tysabri and Gilenya for 2012; 2007 sales converted using /$ of 1.37, 2012 sales and 2017e sales converted using /$ of
6 MS Market in a State of Transition Presents Opportunities Multiple Sclerosis Market Features In 2005 Today 2 Mechanisms of Action 4 Marketed Products 1 Mode of Administration More Acceptance of Disease Activity 7 Mechanisms of Action 10 Marketed Products 3 Modes of Administration Greater Treatment Urgency Increasing diversity of therapeutic options allowing a more individualized treatment approach 6
7 MS Treatment Options Have Increased: Oral and Intravenous Products Share Has Grown Evolution of MS Market H (1) H (2) 96% 4% Injectable Therapies (3) Intravenous Therapies (4) Orals (5) 74% 15% 11% Total Half Year Sales 2.4bn Total Half Year Sales 5.9bn (1) Company reported sales of Avonex, Betaseron /Betaferon, Copaxone, Rebif and Tysabri converted using /$ rate of 1.33 (2) Company reported sales of MS products in H Aubagio, Betaseron, Copaxone, Rebif converted using /$ rate of 1.31 (3) Injectable therapies include Avonex, Betaseron /Betaferon, Copaxone, Rebif, Extavia (4) Intravenous therapies include Tysabri (5) Oral therapies include Aubagio, Gilenya and Tecfidera 7
8 Transition to Oral and Intravenous Therapies Expected to Continue Oral therapy (2) share projected to increase four-fold to nearly 40% of the MS market by 2017 driven by new entrants Intravenous therapies (3) expected to approach 20% of the market Injectable therapies (4) (ABCRE s) projected to decline by roughly half of current usage by % 75% 60% 45% 30% 15% MS Market Evolution (1,2,3,4) (% market share) 59% Injectables Orals Intravenous 0% e (1) Evaluate Pharma July 2013 (2) Oral category includes Aubagio, Gilenya, Tecfidera, laquinimod, 2 nd Gen S1Ps (3) Intravenous category includes Tysabri, Lemtrada, ocrelizumab, daclizumab (4) Injectable category includes Avonex, Betaseron/Betaferon, Copaxone, Rebif, Extavia, Plegridy 8
9 Clinical Data Highlights Michael Panzara, MD, MPH Therapeutic Area Head of MS & Neurology - Genzyme 9
10 Multiple Sclerosis Results in Significant Brain Injury with Irreversible Consequences Brain MRI Reveals Significant Progression of Atrophy Over 10 Years (1) 42 years-old 52 years-old (1) Courtesy of Beth Fisher and Rick Rudick Cleveland Clinic 10
11 New Treatment Goals - Focus on Patient Outcomes Unmet Needs Symptom Alleviation Halt or reverse damage and disability Improve disease control Convenient treatment regimens to improve compliance Maximize patient outcomes New Goals Decrease MS activity and improve quality of life Promote repair, remyelination, durable disability improvement Freedom from disease activity Dosing options, new routes of administration, less frequent dosing Superior effectiveness and favorable benefit/risk vs. existing treatment 11
12 Once-Daily Oral Therapy with Robust Efficacy TEMSO STUDY (1) TOWER STUDY (3) Annualized Relapse Rate (2) Annualized Relapse Rate (2) % p= % p= n=363 n=358 n=388 n=370 Placebo Aubagio 14mg Placebo Aubagio 14mg (1) O Connor PW et al. N Engl J Med 2011;365: (2) Adjusted for Expanded Disability Status Scale score strata and region at baseline and takes duration of treatment into account (3) Kappos L et al. Mult Scler J 2012;18:(S4)9-53(153) 12
13 Only Oral Therapy to Show Significant Effect on Disability in Two Phase III Trials TEMSO STUDY (1) TOWER STUDY (5) Reduction in Progression of Disability (2) Reduction in Progression of Disability (2) % (3) p= (4) -31.5% (3) p= (4) n=363 n=358 n=388 n=370 Placebo Aubagio 14mg Placebo Aubagio 14mg (1) O Connor PW et al. N Engl J Med 2011;365: (2) At Week 108 (3) Derived using Cox proportional hazard model with treatment, EDSS strata at baseline and region as covariates (4) Derived from log-rank test with stratification of EDSS strata at baseline and region (5) Kappos L et al. Mult Scler J 2012;18:(S4)9-53(153) 13
14 Long-term Efficacy and Safety Supported by TEMSO Extension Trial TEMSO extension trial included patients receiving Aubagio for up to 9 years (up to 7 years extension treatment) No new or unexpected safety signals emerged during the study TEMSO (1) Annualized Relapse Rate TEMSO Extension Study (2) Annualized Relapse Rate Measured clinical and MRI disease activity remained low in patients continuing on study treatment Placebo 14mg Placebo/ 14mg 14mg/ 14mg (1) Adjusted for Expanded Disability Status Scale score strata and region at baseline and takes duration of treatment into account (2) Freedman, M et al. Mult Scler J 2013; 19:(S1)
15 Similar Incidence of SAEs Among Aubagio and Placebo-treated Patients in Clinical Trials The Aubagio label (1) includes: Risk of teratogenicity (based on animal data) and hepatotoxicity ALT elevations Alopecia Diarrhea Influenza Nausea Paresthesia SAE: Serious Adverse Event (1) Adapted from U.S. Prescribing Information and European SmPC 15
16 Potentially Rebalances the Immune System Selectively targets CD52 protein, depleting B and T cells responsible for MS inflammatory process A distinctive pattern of lymphocyte repopulation occurs over time (1) May reduce inflammatory processes in MS and have disease modifying effects Supported by durable efficacy after two short treatment courses CD4 Treg Cell Counts (%) Relative Proportion of T Cells Increased with T-Reg Phenotype (2) Months on Therapy Lemtrada 12 mg/day Rebif Lemtrada has been granted marketing authorization by the European Commission and is under review by the regulatory authorities in the U.S. The mechanism by which it exerts therapeutic effect in multiple sclerosis is unknown. Lemtrada is developed in collaboration with Bayer HealthCare (1) Cox AL et al. Eur J Immunol 2005;35: , Hu Y et al. Immunology 2009;128:260-70, Havari E et al. ECTRIMS 2010, Jones JL et al. Brain 2010;133: (2) Hartung HP et al. Mult Scler J 2012; 18:(S4)
17 Active Comparator Set High Bar for Success CARE-MS I (1) CARE-MS II (2) Randomized Patients Study Duration 2 years 2 years Patient Population Treatment naïve Relapsed on prior treatment Treatment Arms Lemtrada vs. Rebif Lemtrada vs. Rebif (1) Coles AJ et al. Lancet. 2012;380(9856): (2) Cohen JA et al. Lancet. 2012;380(9856):
18 Significant Comparative Efficacy Results with Unique Annual Dosing Regimen CARE-MS I (1) CARE-MS II (2) Annualized Relapse Rate Annualized Relapse Rate % p< % p< n=187 n=376 n=202 n=426 Rebif Lemtrada Rebif Lemtrada (1) Coles AJ et al. Lancet. 2012;380(9856): (2) Cohen JA et al. Lancet. 2012;380(9856):
19 Percentage of Patients with SAD Slowed Accumulation of Disability vs. Rebif (1) HR 0.58 Time to SAD (1,2) CARE-MS II Treatment effect: 42% p= Rebif Lemtrada 12 mg/day 21.1% 12.7% HR: Hazard Ratio SAD: Sustained Accumulation of Disability (1) CARE-MS I study in treatment-naïve patients did not show a significant reduction in sustained accumulation of disability (2) Cohen J et al. AAN 2012:platform presentation of CARE-MS II. 19
20 Percentage of Patients with SRD Improvement in Pre-Existing Disability: 6-Month Sustained Reduction in Disability Data suggests that improvement in pre-existing disability was more likely with Lemtrada than Rebif regardless of which functional system was impaired by prior MS disease activity (1) All functional systems contributed to EDSS improvement (1) HR: 2.57 p= Month SRD CARE-MS II (2) Rebif Lemtrada 12 mg 28.8% 12.9% Follow-up Month RRMS: Relapse Remitting Multiple Sclerosis (1) Brinar, V ECTRIMS 2013 (P649) (2) Cohen J AAN 2012:platform presentation of CARE-MS-II 20
21 Percentage of Patients with SRD Durable Effect on Sustained Reduction in Disability Through Year 3 More than 1/3 of Lemtrada treated patients in CARE-MS II extension study attained sustained disability improvement by Year Month SRD (1) CARE-MS II Extension Study 29% 35% Approximately 80% of patients did not receive re-treatment during Year Fewer than 3% received another disease modifying treatment in Year Follow-up Month (1) Hartung HP ECTRIMS 2013(P592) 21
22 Safety Experience from MS Development Program Infusion-associated reactions very common Premedication reduced/alleviated symptoms Infections common in both groups More common with Lemtrada, low number of serious events Autoimmune events, some serious Detected via risk management plan allowing early diagnosis and treatment 22
23 Significant Global Regulatory Milestones Achieved EU approved for adult patients with RRMS New Active Substance designated by EMA providing 10 years of data exclusivity in the EU EU approved for patients with RRMS with active disease as defined by clinical or imaging features (1) FDA approved for adult patients with relapsing forms of multiple sclerosis FDA decision expected in late Q Also approved in Australia, Mexico, Argentina, Chile, South Korea Regulatory reviews ongoing in several other regions RRMS: Relapse Remitting Multiple Sclerosis (1) Not indicated for treating non-active patients and those stable on therapy 23
24 Global Launch Update Bill Sibold SVP, Head of Multiple Sclerosis - Genzyme 24
25 Genzyme s Critical Success Factors in MS Products People Approach Lemtrada and Aubagio are highly differentiated novel products Fulfill unmet needs Well positioned for an evolving market Accomplished team Leveraging experienced Sanofi MS sales reps in European countries Strong commitment and relationships Science driven and patient focused Long term partners Be leaders 25
26 Encouraging U.S. Launch Trends Cumulative U.S. Weekly TRx (1) Aubagio : Quarterly Sales 60,000 Tecfidera 44m (2) Gilenya 33m 40,000 Aubagio 20m 20,000 7m Week 1 Tecfidera Launch Week 48 Q Q Q Q3 2013e (1) IMS Weekly Total Prescriptions (2) Q Aubagio quarterly sales figure is an estimate to be validated when company earnings are released on October 30,
27 Broad Based Patient Demand ~20% patients prescribed Aubagio were treatmentnaïve (2) Aubagio Prior Therapy (1) (Enrolled Patients) >80% of patients switched to Aubagio were most recently on ABCR s Most frequently cited reasons for initiating Aubagio (2) Oral administration Once-daily dosing Needle Fatigue/Phobia 14.1% 22.0% Other 2.2% 8.5% 30.6% 17.4% 3.9% 1.3% DMT: Disease Modifying Therapy (1) Based on data collected at Genzyme's MS One to One Patient and Provider Support Center, Sep 2012-Sep 2013 (2) BioTrends Research Group, LaunchTrends : Aubagio (teriflunomide) - Multiple Sclerosis (Wave 3)
28 Launching a Global MS Franchise (1) 2012 Selected Markets Selected Markets 2014 (1) Timing of regulatory approvals and country reimbursement policies may impact projected launch timelines 28
29 Ready to Launch Our MS Franchise in the EU Aubagio and Lemtrada approved Field forces hired and trained Patient support infrastructure and programs in-place First product shipments First EU sales in October
30 Committed to Being Leaders in MS Multiple Sclerosis market is significant and growing New therapies, satisfying the unmet needs of convenient administration and increased efficacy, to drive growth Genzyme uniquely placed to seize opportunities in Multiple Sclerosis Multiple Sclerosis team with proven track record Aubagio and Lemtrada are positioned for success in an evolving market 30
31 Q&A SESSION 31
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. November 2011 Neil Warma President & CEO Forward-Looking Statements This presentation contains forward-looking statements which are made pursuant to the safe harbor provisions
More informationAubagio (teriflunomide tablets) Policy Number: Last Review: 07/2017 Origination: 07/2014 Next Review: 07/2018
Aubagio (teriflunomide tablets) Policy Number: 5.01.614 Last Review: 07/2017 Origination: 07/2014 Next Review: 07/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for
More informationSESSION VI THE CHALLENGE OF NEW TREATMENTS THE PHARMA INDUSTRY
SESSION VI THE CHALLENGE OF NEW TREATMENTS THE PHARMA INDUSTRY Bruno C. Musch, MD PhD Baveno, Italy November 30th, 2013 DISCLOSURE OF INTEREST Dr.Musch is currently Medical Director in GENENTECH/Roche,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Betaseron, Extavia) Reference Number: CP.CPA.331 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial Coding Implications Revision Log See Important Reminder
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Betaseron, Extavia) Reference Number: CP.PHAR.256 Effective Date: 08.01.16 Last Review Date: 05.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at
More informationLemtrada (alemtuzumab)
Lemtrada (alemtuzumab) Policy Number: 5.02.517 Last Review: 7/2018 Origination: 8/2015 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Lemtrada
More informationClinical Policy: Ocrelizumab (Ocrevus) Reference Number: CP.PHAR.335 Effective Date: Last Review Date: 05.18
Clinical Policy: (Ocrevus) Reference Number: CP.PHAR.335 Effective Date: 04.01.17 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationIntroducing MN-166 Multiple Sclerosis. July 9, 2008
Introducing MN-166 A New Treatment Paradigm for Multiple Sclerosis July 9, 2008 MediciNova, Inc. 2008 Forward-Looking Statements Statements in this presentation that are not historical in nature constitute
More informationDeutsche Bank Healthcare Conference
Deutsche Bank Healthcare Conference Jérôme Contamine, Executive Vice President, Chief Financial Officer Boston May 4, 2017 Forward Looking Statements This presentation contains forward-looking statements
More informationEXANE Conference. Jérôme Contamine, Executive Vice President, Chief Financial Officer. Paris June 13, 2017
EXANE Conference Jérôme Contamine, Executive Vice President, Chief Financial Officer Paris June 13, 2017 Forward Looking Statements This presentation contains forward-looking statements as defined in the
More informationPrior Authorization Form
5/2/2017 Prior Authorization Form INTOTAL HEALTH PLAN (SPC) Multiple Sclerosis MMT SGM This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Ocrevus) Reference Number: CP.PHAR.335 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationCredit Suisse Healthcare Conference
Credit Suisse Healthcare Conference Bill Sibold Executive Vice President, Sanofi Genzyme Scottsdale, Arizona - November 8, 2017 Forward Looking Statements This presentation contains forward-looking statements
More informationClinical Policy: Teriflunomide (Aubagio) Reference Number: CP.PHAR.262 Effective Date: Last Review Date: 05.18
Clinical Policy: (Aubagio) Reference Number: CP.PHAR.262 Effective Date: 08.01.16 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Aubagio) Reference Number: CP.PHAR.262 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationUpdate on New MS Therapeutics
Update on New MS Therapeutics William Meador, MD Assistant Professor AAN August 2017 Meeting Disclosures Clinical Trial Involvement: SPRINT-MS Trial MediciNova, ibudilast LemCog Sanofi/Genzyme, alemtuzumab
More informationApproved by: Pharmacy and Therapeutics Quality Management Subcommittee Effective Date: Department of Origin: Pharmacy. Date approved: 06/21/17
Integrated Healthcare Services and Criteria Document: Reference #: PC/B016 Page: 1 of 4 PRODUCT APPLICATION: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA
More informationApproval of a drug under this criteria document does not ensure full coverage of the drug.
Criteria Document: Reference #: PC/B016 Page: 1 of 4 and Therapeutics Quality PRODUCT APPLICATIO: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tysabri) Reference Number: CP.CPA.206 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Coding Implications Revision Log See Important Reminder at the end
More informationMS Injectable Drugs
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: MS Injectable Drugs Page: 1 of 5 Last Review Date: November 30, 2018 MS Injectable Drugs Description
More informationMultiple Sclerosis Agents Drug Class Prior Authorization Protocol
Multiple Sclerosis Agents Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 This policy has been developed through review
More informationOutline. References. Marshall,1
Outline Multiple Sclerosis: More Than Your ABC s Janene L. Marshall, PharmD, BCPS Clinical Associate Professor Internal Medicine Clinical Pharmacist Chicago State University College of Pharmacy J-marshall@csu.edu
More information2018 ECTRIMS Data Review Call. October 2018
2018 ECTRIMS Data Review Call October 2018 TG Therapeutics Michael S. Weiss, CEO Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private
More informationTechnology appraisal guidance Published: 22 January 2014 nice.org.uk/guidance/ta303
Teriflunomide for treating relapsing remitting multiple sclerosis Technology appraisal guidance Published: 22 January 2014 nice.org.uk/guidance/ta303 NICE 2018. All rights reserved. Subject to Notice of
More informationMultiple Sclerosis Agents
Multiple Sclerosis Agents Policy Number: 5.01.614 Last Review: 09/2018 Origination: 07/2014 Next Review: 09/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationNational MS Society Information Sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Interferons The interferons are a group of natural proteins that are produced by human cells in response to viral infection
More informationBeta interferon and glatiramer acetate for treating multiple sclerosis (review of TA32)
Public slides part 1 (Redacted) Beta interferon and glatiramer acetate for treating multiple sclerosis (review of TA32) 3 rd Appraisal Committee meeting Committee B, 16 th November 2017 Previous Appraisal
More informationCommon Drug Review Pharmacoeconomic Review Report
Common Drug Review Pharmacoeconomic Review Report October 2014 Drug Teriflunomide (Aubagio) (14 mg film-coated tablet) Indication Teriflunomide is indicated as monotherapy for the treatment of patients
More informationNatalizumab (Tysabri) Humanized, MAb Against α 4 subunit of α 4 β 1 Integrin. Multiple Sclerosis Treatment Update
Natalizumab (Tysabri) Humanized, MAb Against α 4 subunit of α 4 β 1 Integrin Complementarity-Determining Regions (CDRs) Multiple Sclerosis Treatment Update CDR grafted from murine Ab Human IgG 4 framework
More informationLEMTRADA (ALEMTUZUMAB)
LEMTRADA (ALEMTUZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2017D0023O Effective Date: June 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Alemtuzumab, dimethyl fumarate, laquinimod and teriflunomide for the treatment of relapsing forms of multiple
More informationA blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
More informationS.E.A.R.C.H. SM Patient Workbook
S.E.A.R.C.H. SM Patient Workbook How to S.E.A.R.C.H. SM for the Right MS Therapy For You! What is S.E.A.R.C.H. SM? The first treatment for relapsing-remitting multiple sclerosis (RRMS) was approved by
More informationBiogen Idec Neurology Pipeline. Alfred Sandrock, MD, PhD SVP, Neurology Research & Development
Biogen Idec Neurology Pipeline Alfred Sandrock, MD, PhD SVP, Neurology Research & Development March 25, 2009 Robust Neurology Pipeline Neurology Multiple Sclerosis Discovery Pre-Clinical Phase 1 Phase
More informationThere are currently 4 US Food and Drug
DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS* Benjamin M. Greenberg, MD, MHS ABSTRACT Four major disease-modifying therapies are discussed within the context of relapsing and remitting
More informationDisease-Modifying Therapies for Relapsing- Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value
Disease-Modifying Therapies for Relapsing- Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value Response to Public Comments on Draft Evidence Report January 26, 2017 Institute
More informationNational Horizon Scanning Centre. Cladribine (Movectro) for multiple sclerosis; relapsing-remitting. April 2008
Cladribine (Movectro) for multiple sclerosis; relapsing-remitting April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationMAY 2017 RESEARCH U P D A T E
MAY 2017 MS RESEARCH U P D A T E MS RESEARCH U P D A T E Written and compiled by Michelle Fabian, MD and Stephen Krieger, MD Includes additional material by Margaret M. McCormick, RN, BSN, MSCN Reviewed
More informationLEMTRADA (ALEMTUZUMAB)
LEMTRADA (ALEMTUZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0023P Effective Date: April 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationFirst Quarter 2018 Financial Results & Update
First Quarter 2018 Financial Results & Update April 26, 2018 Forward-Looking Statements and Non-GAAP Financial Information 2 Certain statements set forth in this presentation constitute forward-looking
More informationMAY 2018 RESEARCH U P D A T E
MAY 2018 MS RESEARCH U P D A T E MS RESEARCH U P D A T E Written and compiled by Tom Garry with Stephen Krieger, MD and Michelle Fabian, MD Reviewed by Jack Burks, MD Edited by Susan Courtney The 2018
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Tysabri, (natalizumab), Lemtrada (alemtuzumab), Page 1 of 21 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See Also: Tysabri (natalizumab), Lemtrada (alemtuzumab),
More informationFourth Quarter and Full Year Financial and Operational Results Conference Call March 21, 2018
Fourth Quarter and Full Year 2017 Financial and Operational Results Conference Call March 21, 2018 Copyright Akari Therapeutics, Plc - 2018 Disclaimers Certain statements in this presentation constitute
More informationFirst Quarter 2018 Financial Results. May 8, 2018
First Quarter 2018 Financial Results May 8, 2018 Agenda Introduction Sarah Carmody, Senior Director of Investor Relations Corporate Update Craig Wheeler, President and Chief Executive Officer First Quarter
More informationJ.P. Morgan Healthcare Conference. January 15, 2009
J.P. Morgan Healthcare Conference January 15, 2009 Facet Biotech Corporation Forward-looking Statements This presentation contains forward-looking statements involving risks and uncertainties and Facet
More informationGEN-003. Positive Phase 2b Clinical Efficacy Results. Immunotherapy Candidate for Genital Herpes. 12-Month Top-line Results
GEN-003 Positive Phase 2b Clinical Efficacy Results Immunotherapy Candidate for Genital Herpes 12-Month Top-line Results Disclaimer This presentation contains forward-looking statements that are within
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 April 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 April 2011 COPAXONE 20 mg/ml, solution for injection, pre-filled syringe B/28 (CIP code: 363 840-1) Applicant: SANOFI-AVENTIS
More informationThis Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. Multiple Sclerosis Agents Ampyra Aubagio Avonex Betaseron Copaxone Extavia Gilenya Glatopa Plegridy Rebif Tysabri
More informationThe Cost-Effectiveness of Treatment Options for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: Modeling Analysis Plan
The Cost-Effectiveness of Treatment Options for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: Modeling Analysis Plan October 7, 2016 Prepared for Institute for Clinical and Economic Review,
More informationAntisense Therapeutics Ltd ASX:ANP January 2017
Antisense Therapeutics Ltd ASX:ANP January 2017 Forward Looking Statements This presentation contains forward-looking statements regarding the Company s business and the therapeutic and commercial potential
More informationJanuary (San Francisco, CA) January 8, 2018
January 2017 J.P. Morgan 36 th Annual Management Healthcare Presentation Conference (San Francisco, CA) January 8, 2018 DISCLAIMER Certain information contained in this presentation relates to or is based
More informationSanofi to Acquire Bioverativ A Strategically and Financially Compelling Acquisition in Specialty Care
Sanofi to Acquire Bioverativ A Strategically and Financially Compelling Acquisition in Specialty Care January 22, 2018 Forward Looking Statements This presentation contains forward-looking statements.
More informationCortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly
Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly May 14, 2015 Goteborg, Sweden and Trevose, Pa., USA and Victoria, Australia Cortendo AB (publ) [ticker: CORT
More informationExtending Our Leadership Position in Multiple Sclerosis. December 12, 2018
Extending Our Leadership Position in Multiple Sclerosis December 12, 2018 1 Forward-Looking Statements This presentation contains forward-looking statements, including statements relating to: our strategy
More informationThe MS Disease- Modifying Medications. General information
The MS Disease- Modifying Medications General information Current as of April 2013. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication, please
More informationTechnology appraisal guidance Published: 27 August 2014 nice.org.uk/guidance/ta320
Dimethyl fumarate ate for treating relapsing-remitting multiple sclerosis Technology appraisal guidance Published: 27 August 2014 nice.org.uk/guidance/ta320 NICE 2018. All rights reserved. Subject to Notice
More informationClinical Policy: Multiple Sclerosis Reference Number: CP.CPA.206 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Reference Number: CP.CPA.206 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationHelen C. Pervanas, Pharm.D. Associate Professor of Pharmacy Practice MCPHS Worcester/Manchester
Helen C. Pervanas, Pharm.D. Associate Professor of Pharmacy Practice MCPHS Worcester/Manchester helen.pervanas@mcphs.edu Objectives Describe the pathophysiology, diagnosis and prognosis of MS Discuss disease
More informationDrug Name (select from list of drugs shown) Tysabri (natalizumab) Quantity Frequency Strength Route of Administration
04/30/2014 Prior Authorization Form MERCY CARE PLAN (MEDICAID) Tysabri (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationMultiple Sclerosis: KOL Insight 2016
Multiple Sclerosis: KOL Insight 2016 Multiple Sclerosis: KOL Insight 2016 BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio
More informationCADTH Canadian Drug Expert Committee Recommendation
CADTH COMMON DRUG REVIEW CADTH Canadian Drug Expert Committee Recommendation (Final) GLATIRAMER ACETATE (GLATECT PENDOPHARM) Indication: Relapsing-Remitting Multiple Sclerosis RECOMMENDATION: The CADTH
More informationAchillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs
November 1, 2017 Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs Robust balance sheet to support global expansion of ACH-4471 clinical development program
More informationEvidence Review Group s Report Dimethyl fumarate for treating relapsing-remitting multiple sclerosis
Evidence Review Group s Report Dimethyl fumarate for treating relapsing-remitting multiple sclerosis Produced by CRD and CHE Technology Assessment Group Authors Gill Norman, Research Fellow, CRD Stephen
More informationLicense Agreement of Tildrakizumab for Psoriasis in Europe
License Agreement of Tildrakizumab for Psoriasis in Europe July 28 th 2016 Disclaimer This document has been prepared by Almirall, S.A. (the Company ) exclusively for use during the presentation. This
More informationPipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016
For more information contact us Pipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016 Copyright. 2016 Advera Health Analytics, Inc. All rights reserved.
More informationAdvances in Immunomodulatory Therapy for Multiple Sclerosis
Advances in Immunomodulatory Therapy for Multiple Sclerosis Sona Narula, MD Children s Hospital of Philadelphia, Philadelphia, Pennsylvania Abstract Significant research has been directed toward the development
More informationBayer HealthCare Investor Day Growth Through Our Portfolio of Marketed Products (1)
Bayer HealthCare Investor Day 2007 Growth Through Our Portfolio of Marketed Products (1) Gunnar Riemann Business Units Oncology, Specialized Therapeutics, Cardiology/Hematology Member of the Board Bayer
More informationCAMBRIDGE, Mass.--(BUSINESS WIRE)--
1 von 6 20.12.2016 17:44 By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes Tue 20 Dec 2016 16:43 - UK Markets are closed Press Release: Sanofi Genzyme
More informationSupplementary Appendix A: Cost-effectiveness Model: Additional Input Parameter Values
Supplementary Appendix A: Cost-effectiveness Model: Additional Input Parameter Values Appendix A: Cost-effectiveness Model: Additional Input Parameter Values Detailed Input Tables Table A.1: Annual Probability
More informationInducing tolerance to Campath 1H (alemtuzumab) in the treatment of multiple sclerosis
Inducing tolerance to Campath 1H (alemtuzumab) in the treatment of multiple sclerosis Alasdair Coles Herman Waldmann & Geoff Hale Universities of Cambridge & Oxford Alemtuzumab (Campath 1H) Humanised
More informationTrubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007
Trubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007 Peter Thompson, M.D., FACP President, CEO and Chairman Trubion Pharmaceuticals, Inc. Safe Harbor
More informationThe Latest Therapies for MS: Weighing Respective Benefits and Risks
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/frontlines-multiple-sclerosis/the-latest-therapies-for-ms-weighingrespective-benefits-and-risks/9639/
More informationGenentech Contacts: Media: Tara Cooper (650) Investor: Kathee Littrell (650)
NEWS RELEASE Genentech Contacts: Media: Tara Cooper (650) 225-5505 Investor: Kathee Littrell (650) 225-1034 XOMA Media/Investor Contacts: Laura Zobkiw (510) 204-7273 Peter Davis (510) 204-7231 FDA APPROVES
More informationSynthetic Biologics Reports Year End 2012 Financial Results
April 16, 2013 Synthetic Biologics Reports Year End 2012 Financial Results -- Strengthening Infectious Disease Portfolio to Include C. difficile, Pertussis and Acinetobacter Targets -- ROCKVILLE, Md.,
More informationARIKAYCE U.S. FDA Approval
S E P T E M B E R 2 8, 2 0 1 8 ARIKAYCE U.S. FDA Approval Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the
More informationRESEARCH/CLINICAL UPDATE
National Multiple Sclerosis Society 733 Third Avenue New York, New York 10017-3288 Tel +1 212.986.3240 Fax +1 212.986.7981 E-mail nat@nmss.org nationalmssociety.org October 30, 2007 RESEARCH/CLINICAL UPDATE
More informationBiogen Idec Q Earnings Conference Call and Webcast. July 22 nd 2008
Biogen Idec Q2 2008 Earnings Conference Call and Webcast July 22 nd 2008 Forward Looking Statements This presentation includes forward-looking statements about: our 2008 guidance and our financial and
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Multiple Sclerosis Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Multiple Sclerosis Agents Tysabri (natalizumab) and Lemtrada (alemtuzumab),
More informationInternational Progressive Multiple Sclerosis Collaborative : Update on Research Strategy
International Progressive Multiple Sclerosis Collaborative : Update on Research Strategy Increasing disability Increasing disability Progressive Forms of MS Many MS patients begin with a relapsing form
More informationAntibody therapy of multiple sclerosis Prof. Alastair Compston Dr. Alasdair Coles
Antibody therapy of multiple sclerosis & Department of Clinical Neurosciences, School of Clinical Medicine, University of Cambridge, U.K. 1 The story of multiple sclerosis: 1838-1993 2 The symptoms of
More informationA Multiple Treatment Comparison of Eleven Disease- Modifying Drugs Used for Multiple Sclerosis
Original Article J Clin Med Res. 2018;10(2):88-105 A Multiple Treatment Comparison of Eleven Disease- Modifying Drugs Used for Multiple Sclerosis Vida Hamidi a, Elisabeth Couto a, Tove Ringerike a, Marianne
More informationInnovating Antibodies, Improving Lives. 37 th Annual J.P. Morgan Healthcare Conference January 9, 2019
Innovating Antibodies, Improving Lives 37 th Annual J.P. Morgan Healthcare Conference January 9, 2019 Forward Looking Statement This presentation contains forward looking statements. The words believe,
More informationTysedmus, a Registry of Multiple Sclerosis patients exposed to Natalizumab
PHARMACOVIGILANCE AND REGISTRY PROGRAMMES Tysedmus, a Registry of Multiple Sclerosis patients exposed to Natalizumab Eric Van Ganse Pharmacoepidemiology, CHU-Lyon France OUTLINE I. GOOD REGISTRY PRACTICE
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Multiple Sclerosis Agents Page 1 of 17 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Multiple Sclerosis Agents Tysabri (natalizumab) and Lemtrada (alemtuzumab)
More informationJ.P. Morgan 36 th Annual Healthcare Conference. January 10, 2018
J.P. Morgan 36 th Annual Healthcare Conference January 10, 2018 Forward Looking Statements BioCryst s presentation may contain forward looking statements, including statements regarding future results,
More informationCladribine. Spirella Building, Letchworth, SG6 4ET reg charity no
Cladribine Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Cladribine Date of issue: February 2009 Contents Section Page 1. Introduction 1 2. How cladribine
More informationOral NT-KO-003 for the Treatment of Multiple Sclerosis
Oral for the Treatment of Multiple Sclerosis Madrid, 27 de noviembre de 2013 Content 1. The Company 2. The Product a) Target Indications b) Innovative mechanisms of action c) Differential features facing
More information2018 ASCO Conference Call June 2, 2018
2018 ASCO Conference Call June 2, 2018 1 Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the safe harbor provisions
More informationAdvancing Mitochondrial Medicine. Günther Metz, SVP Business Development
Advancing Mitochondrial Medicine Günther Metz, SVP Business Development Disclaimer 2 This presentation is not and under no circumstances to be construed as a solicitation, offer, or recommendation, to
More informationRoche to present new data at AAN reinforcing efficacy and safety of newly FDAapproved OCREVUS (ocrelizumab) in two types of multiple sclerosis
Investor Update Basel, 19 April 2017 Roche to present new data at AAN reinforcing efficacy and safety of newly FDAapproved OCREVUS (ocrelizumab) in two types of multiple sclerosis Data presentations will
More informationCIBMTR Center Number: CIBMTR Recipient ID: RETIRED. EBMT Center Identification Code (CIC): Today s Date:
Multiple Sclerosis Pre-HSCT Data EBMT Center Identification Code (CIC): Today s Date: Sequence Number: Date Received: Registry Use Only Date of HSCT for which this form is being completed: & 20 20 HSCT
More informationISPOR 18th Annual European Congress Tuesday 10 November,13:45-14:45
ISPOR 18th Annual European Congress Tuesday 10 November,13:45-14:45 Introduction Alastair Kent, OBE, Genetic Alliance UK, London, UK Recent HTA decisions Jacco Keja, PhD, IMS Health, Rotterdam, The Netherlands
More informationADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationDUCHENNE MUSCULAR DYSTROPHY CLINICAL DEVELOPMENT PROGRAM
DUCHENNE MUSCULAR DYSTROPHY CLINICAL DEVELOPMENT PROGRAM Dana R. Martin, PharmD Sarepta Therapeutics PPMD ANNUAL CONNECT CONFERENCE ORLANDO, FLORIDA JUNE 27, 2016 FORWARD LOOKING STATEMENTS This presentation,
More informationClinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
Journal of Central Nervous System Disease Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Clinical Utility of Glatiramer Acetate in the Management
More informationtrial. Key trial data points:
February 23, 2015 ADMA Biologics Announces Positive Data on Primary and Secondary Endpoints from its Pivotal Phase III Clinical Trial for RI-002 at the AAAAI Medical Conference RAMSEY, N.J., Feb. 23, 2015
More informationResults to be Presented at LDN WORLD Symposium in February Initiation of Repeat-Dose Pompe Study Anticipated in 3Q13
Amicus Therapeutics Announces Positive Results from All Four Cohorts in Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Co-Administration Study for Pompe Disease Strong Proof-of-Concept Data for Chaperone
More informationClinical Trial Paradigms in CNS Gene Therapy. Bernard Ravina, MD, MS Chief Medical Officer, Praxis Precision Medicines October 16, 2018
Clinical Trial Paradigms in CNS Gene Therapy Bernard Ravina, MD, MS Chief Medical Officer, Praxis Precision Medicines October 16, 2018 Disclosures Employee, Praxis Medicines Advisor, Voyager Therapeutics
More informationpsivida Corp PSDV June 2016
psivida Corp PSDV June 2016 Safe Harbor Statement Safe Harbor Statement SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking,
More information